Zoledronic acid

Generic Name: Zoledronic acid

Brand Names: Aclasta, Reclast, Zometa, Zoledronic Acid Accord, Zoledronic acid Actavis, Zoledronic acid medac, Zoledronic acid Teva, Zoledronic Acid Hospira, Zoledronic acid Mylan

Drug Type: Small Molecule

Chemical Formula: C_₅H_₁₀N_₂O_₇P_₂

CAS Number: 118072-93-8

Unique Ingredient Identifier: 70HZ18PH24

Background: Zoledronic acid, or CGP 42'446, is a third generation, nitrogen containing bisphosphonate similar to ibandronic acid, minodronic acid, and risedronic acid. Zoledronic acid is used to treat and prevent multiple forms of osteoporosis, hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, and Paget’s disease of bone. Zoledronic acid was first described in the literature in 1994.

Zoledronic acid was granted FDA approval on 20 August 2001.

Indication: Zoledronic acid is indicated to treat hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, osteoporosis in men and postmenopausal women, glucocorticoid induced osteoporosis, and Paget's disease of bone in men and women. Zoledronic acid is also indicated for the prevention of osteoporosis in post menopausal women and glucocorticoid induced osteoporosis.

Associated Conditions: Bone Metastases, Hypercalcemia of Malignancy, Multiple Myeloma (MM), Osteoporosis, Osteoporosis caused by Glucocorticoid Treatment, Paget's Disease of Bone, Paget’s Disease

Associated Therapies: Bone Mineral Density

Clinical Trials

A Trial of Zoledronic Acid in Patients With Myelofibrosis With Myeloid Metaplasia (MMM)

Phase 2

Completed

Conditions: Myelofibrosis
Myeloid Metaplasia

Interventions: Drug: zoledronic acid

First Posted Date: 2006-02-06

Last Posted Date: 2014-12-09

Lead Sponsor: Universitaire Ziekenhuizen KU Leuven

Target Recruit Count: 17

Registration Number: NCT00287261

Locations: 🇮🇱
RAMBAM Medical Center and Technion, Haifa, Israel
🇦🇺
Cancer Care Services, Brisbane, Queensland, Australia
🇫🇷
Hopital Avicenne and Paris 13 University, Bobigny, France

and more 3 locations

Zoledronate in Treating Patients With Cervical Intraepithelial Neoplasia 2/3 or 3

Phase 1

Terminated

Conditions: Cervical Cancer
Precancerous Condition

Interventions: Other: Placebo (Saline)
Drug: Zoledronate

First Posted Date: 2006-01-18

Last Posted Date: 2017-11-24

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 12

Registration Number: NCT00278434

Locations: 🇺🇸
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States

Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy

Phase 2

Active, not recruiting

Conditions: Prostate Cancer

Interventions: Drug: Transdermal Oestradiol
Drug: Prednisolone
Drug: Celecoxib
Drug: Docetaxel
Drug: ADT
Radiation: Radiotherapy to the prostate
Drug: Zoledronic Acid
Drug: Metformin
Drug: Abiraterone
Drug: Enzalutamide

First Posted Date: 2005-12-22

Last Posted Date: 2023-04-18

Lead Sponsor: Medical Research Council

Target Recruit Count: 11992

Registration Number: NCT00268476

Locations: 🇬🇧
West Suffolk Hospital, Bury St. Edmunds, England, United Kingdom
🇬🇧
Derbyshire Royal Infirmary, Derby, England, United Kingdom
🇬🇧
Russells Hall Hospital, Dudley, England, United Kingdom

and more 115 locations

Using TRAP to Evaluate the Effect of Zometa on Bone Metastasis Due to Lung Cancer

Phase 2

Terminated

Conditions: Metastases
Carcinoma, Non-Small Cell Lung
Carcinoma, Small Cell Lung

Interventions: Drug: zoledronic acid

First Posted Date: 2005-12-14

Last Posted Date: 2018-03-05

Lead Sponsor: University of Louisville

Target Recruit Count: 28

Registration Number: NCT00265200

Locations: 🇺🇸
James Graham Brown Cancer Center, Louisville, Kentucky, United States

Safety and Efficacy Study of Concomitant Radiotherapy and Zoledronic Acid for Bone Metastases Palliation

Phase 1

Completed

Conditions: Bone Metastases
Breast Cancer
Lung Cancer
Prostate Cancer

Interventions: Drug: zoledronic acid

First Posted Date: 2005-12-12

Last Posted Date: 2010-12-21

Lead Sponsor: The Cleveland Clinic

Target Recruit Count: 4

Registration Number: NCT00264420

Higher Frequency Zoledronic Acid in the Treatment of Multiple Myeloma

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Drug: dexamethasone
Drug: thalidomide
Drug: zoledronic acid

First Posted Date: 2005-12-08

Last Posted Date: 2011-07-21

Lead Sponsor: Gleneagles Hospital

Target Recruit Count: 56

Registration Number: NCT00263484

Locations: 🇮🇳
Christian Medical College, Vellore, Tamil Nadu, India
🇮🇳
Tata Memorial Hospital, Mumbai, India
🇰🇷
Chonnam National University Hwasun Hospital, Kwangju, Korea, Republic of

and more 7 locations